Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.59 |
| ▸ | GHSR | Q92847 | 4/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.52 |
| ▸ | CCKAR | P32238 | 1/20 | 0.52 |
| ▸ | CCKBR | P32239 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 2/20 | 0.52 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.50 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.50 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29961801 | 0.97 | PRMT1 (0.58) | PRMT1GHSROPRD1CCKARCCKBR | |
| SCHEMBL30272491 | 0.92 | GHSR (0.58) | GHSRACEERAP2UTS2R | |
| SCHEMBL31741259 | 0.90 | PRMT1 (0.59) | PRMT1GHSROPRD1CCKARCCKBR | |
| SCHEMBL30255956 | 0.90 | ACE (0.58) | PRMT1OPRD1ACEERAP2OPRM1 | |
| SCHEMBL30605164 | 0.90 | ACE (0.59) | OPRD1ACEERAP2OPRM1 | |
| SCHEMBL31541502 | 0.89 | OPRM1 (0.55) | PRMT1GHSROPRD1ACEERAP2 | |
| SCHEMBL30728822 | 0.89 | GHSR (0.61) | GHSRACEUTS2R | |
| SCHEMBL31593270 | 0.88 | GHSR (0.58) | GHSRACEUTS2R | |
| SCHEMBL31433302 | 0.88 | PRMT1 (0.57) | PRMT1GHSROPRD1ERAP2ERAP1 | |
| SCHEMBL9390811 | 0.88 | PRMT1 (0.53) | PRMT1GHSROPRD1CCKARCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12498379-B2 | Solid-phase N-terminal peptide capture and release | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12498379-B2 | Solid-phase N-terminal peptide capture and release | ANPEP, MAX, DNPEP | PRMT1 702/4885GHSR 533/4885OPRD1 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.